Le Lézard
Classified in: Health
Subject: FDA

United Imaging Healthcare uPMR 790 HD TOF PET/MR Cleared by FDA


HOUSTON, May 8, 2019 /PRNewswire/ -- United Imaging Healthcare (UIH), an international leader in advanced medical imaging and radiotherapy equipment, announced the U.S. Food and Drug Administration (FDA) clearance of the uPMR 790 HD TOF PET/MR. uPMR 790 redefines clinical routine imaging for PET/MR with the capability to scan a whole body within 20 minutes, balancing patient comfort with high-quality imaging. With the uPMR 790, United Imaging Healthcare demonstrates its commitment to advance precision medicine in the fields of neurology, oncology, and cardiology.

The next generation platform of the uPMR 790 delivers state-of-the-art PET and MR performance that rises above the current technology standards. The HD TOF PET platform is based on digital silicon photomultipliers (SiPMs) and lutetium-yttrium oxyorthosilicate (LYSO) crystals, offering a 2.8 mm NEMA PET spatial resolution with time-of-flight (TOF) technology and a large 32cm axial field-of-view. When this technology is combined with compressed sensing for whole body isotropic 3D MR imaging, it results in fast simultaneous whole-body PET and MR scans. This technology redefines PET/MR imaging by offering clinicians high isotropic spatial resolution to visualize small lesions while accelerating acquisition times to maximize patient comfort.

uPMR 790 also offers cutting-edge imaging for research, including theranostics and neuroscience which benefit from an increase in sensitivity, resolution, and coverage. United Imaging Healthcare's uSync Research platform enables additional opportunities for research in areas such as simultaneous tracking of PET and MRI tracers, real-time cardiac PET/MR, functional neurological PET/MR, and multi-parametric radiometrics.

"The uPMR 790 sets a new standard for simultaneous PET and MR performance by not only enhancing the precision and resolution of scans, but by also dramatically changing the patient experience," said Jeffrey M. Bundy, Ph.D., Chief Executive Officer of UIH Solutions. "Today's announcement again delivers on our mission to embed breakthrough innovation across our portfolio. The uPMR is yet another proof point of our commitment to provide more patients in the United States with access to advanced technology and higher standards of care."

ABOUT UIH
United Imaging Healthcare Technology Group Co., Ltd. (UIH) develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment and offers medical IT and intelligent solutions. Founded in 2011 and headquartered in Shanghai, the company has subsidiaries and R&D centers across China, US, and other parts of the world. UIH's vision is to lead healthcare innovation. Through innovation, UIH aims to contribute to bringing equal healthcare for all people worldwide.
To learn more, visit https://www.united-imaging.com.

SOURCE United Imaging Healthcare Co., Ltd.


These press releases may also interest you

at 16:28
Dr. Siva Mohan, Co-Founder and Chief Medical Officer of RazorMetrics, an Austin-based drug cost reduction platform, is the Best Entrepreneur - Health Products & Services Status: Silver Stevie Winner from the American Business Awards. The Stevie®...

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:16
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...

at 16:15
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...



News published on and distributed by: